The Modifiable Risk Factors of Uncontrolled Hypertension in Stroke: A Systematic Review and Meta-Analysis

Arif Setyo Upoyo,1,2 Ismail Setyopranoto,3 and Heny Suseani Pangastuti4

1Faculty of Health Sciences, Jenderal Soedirman University, Indonesia
2Doctoral Program of Nursing, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Indonesia
3Department of Neurology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Indonesia
4Department of Medical and Surgical Nursing, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Indonesia

Correspondence should be addressed to Arif Setyo Upoyo; afkarfadholi@gmail.com

Received 11 November 2020; Revised 16 January 2021; Accepted 8 February 2021; Published 24 February 2021

Academic Editor: Alessandro Stecco

Copyright © 2021 Arif Setyo Upoyo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This review aimed at figuring out the risk factors of uncontrolled hypertension in stroke. Method. This study systematically analyzed the hypertension risk factors available in the ProQuest, EBSCO, and PubMed databases published between 2010 and December 2019. The risk factors’ pooled odds ratio (POR) included in this research was calculated using both fixed and random-effect models. The meta-data analysis was processed using the Review Manager 5.3 (Rev Man 5.3). Result. Of 1868 articles, seven studies were included in this review searched using specific keywords. Based on the analysis results, there were 7 risk factors of uncontrolled hypertension in stroke: medication nonadherence (POR = 2.23 [95% CI 1.71-2.89], p = 0.342; I2 = 6.7%), use of antihypertensive drugs (POR = 1.13 [95% CI 1.19-1.59, p = 0.001; I2 = 90.9%], stage of hypertension (POR = 1.14 [95% CI 1.02-1.27], p = <0.001; I2 = 97.1%), diabetes mellitus (POR = 0.71 [95% CI 0.52-0.99], p = <0.001; I2 = 96.5%), atrial fibrillation (POR = 1.74 [95% CI 1.48-2.04]), p = <0.001; I2 = 93.1%), triglycerides (POR = 1.47 [95% CI 1.23-1.75], p = 0.879; I2 = 0%), and age (POR = 1.03 [95% CI 0.89-1.18], p = <0.001; I2 = 97.5%). There were no bias publications among studies. Medication nonadherence and triglycerides had homogeneous variations, while the others had heterogeneous variations. Conclusion. Medication nonadherence, triglycerides, stage of hypertension, atrial fibrillation, and use of antihypertensive drugs significantly affect the uncontrolled hypertension in stroke.

1. Introduction

Stroke is one main cause of death and disability in many countries [1]. It was globally reported that, in 2013, there were nearly 25.7 million stroke suffers and 10.3 million new stroke cases [2]. The prevalence of stroke in Indonesia annually increases. Based on the Basic Health Research conducted in 2013, the prevalence of stroke was 7 per one thousand people of the population. Meanwhile, in 2018, the prevalence of stroke was 10.9 per one thousand people of the population [3].

The risk factors in stroke include both nonmodifiable and modifiable factors. The nonmodifiable factors include age, sex, race/ethnicity, and genetics. Meanwhile, the modifiable factors include hypertension, diabetes, atrial fibrillation, dyslipidemia, diet, physical activity, obesity, metabolic syndrome, alcohol consumption, and smoking [4, 5].

Controlling the modifiable risk factors in stroke is greatly important to prevent from stroke. The problems faced in controlling the risk factors in stroke include inaccurate knowledge [8], nonoptimal adherence [9, 10], and less awareness to the stroke risks [11].
This study determined the uncontrolled hypertension risk factors in stroke using some studies through a systematic review and meta-analysis to result in stronger conclusions.

2. Method

2.1. Research Design and Samples. This research was quantitatively conducted with a meta-analysis research design. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12]. Meta-analysis was used to figure out the risk factors for the uncontrolled hypertension in stroke. The research samples were the research articles on hypertension risk factors available in the ProQuest, EBSCO, and PubMed databases published between 2010 and December 2019. The inclusion criteria were studies on the uncontrolled hypertension risk factors in stroke with a control case or cohort study. Meanwhile, the exclusion criteria were those not available in the full-text forms.

2.2. Operational Definitions. The variables in this study including the independent variables were the modifiable factors consisting of physical activity, obesity, smoking, alcohol consumption, sodium consumption, saturated fat consumption, diabetes, hypercholesterolemia, triglycerides, knowledge, therapy adherence, and atrial fibrillation. Meanwhile, the nonmodifiable risk factors included age, sex, and family history of hypertension. The dependent variable in this research was the uncontrolled hypertension in stroke. It was considered uncontrolled if the SBP is $\geq 140$ mm Hg and/or the DBP is $\geq 90$ mm Hg [13].

2.3. Research Procedures. This study was conducted by identifying the research articles on the uncontrolled hypertension risk factors in stroke available in the PubMed, ProQuest, and EBSCO databases published between 2010 and December 2019 (Figure 1). Searching was made by entering the following keywords: ((uncontrolled blood pressure OR uncontrolled hypertension) AND (risk factors OR age OR sex OR family history of hypertension OR physical activity OR activity OR body mass index OR obesity OR smoking OR tobacco use OR cigarette OR alcohol consumption OR unhealthy diet OR diet OR trans-fat OR saturated fat OR sodium consumption OR salt consumption OR diabetes OR hypercholesterolemia OR knowledge OR stress OR anxiety OR adherence OR self-care OR self-management OR compliance of therapy) AND (Stroke)).

Figure 1: Flow diagram on the selection processes examining the risk factors of uncontrolled hypertension in stroke.
| First author (year) | Type of study | Period of research | Total subject | Total cases | Risk of factor | OR/RR | CI(95%) | Impact |
|---------------------|---------------|--------------------|---------------|-------------|---------------|-------|---------|--------|
| Chen et al. (2018) [14] | Cohort | NE | 301 | 166 | Medication nonadherence | 2.854 | 1.357-6.005 | |
| Vilaubi et al. (2018) | Cohort | January 2004-May 2005 | 438 | 269 | Guideline nonadherence | 1.66 | 1.02-2.68 | Uncontrolled BP |
| Sarfo et al. (2016) [25] | Retrospective observational study | January 2012-June 2014 | 580 | 178 | Stage of hypertension | 1.31 | 1.17-1.47 | Uncontrolled BP |
| Sarfo et al. (2016) [25] | Retrospective observational study | January 2012-June 2014 | 580 | 178 | Use of antihypertension | 1.3 | 1.06-1.60 | |
| Nidhinandana et al. (2014) [26] | Retrospective observational study | February 2010-January 2011 | 558 | 349 | Diabetes mellitus | 0.18 | 0.11-0.29 | |
| Nidhinandana et al. (2014) [26] | Retrospective observational study | February 2010-January 2011 | 558 | 349 | Stage 1 of HT | 0.3 | 0.15-0.59 | |
| Nidhinandana et al. (2014) [26] | Retrospective observational study | February 2010-January 2011 | 558 | 349 | Stage 2 of HT | 0.24 | 0.12-0.29 | |
| Nidhinandana et al. (2014) [26] | Retrospective observational study | February 2010-January 2011 | 558 | 349 | Use of antihypertension | 0.53 | 0.33-0.85 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | BP medications nonadherence | 2.45 | 1.738-3.454 | Uncontrolled SBP |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Age >55 years old | 1.666 | 1.376-2.017 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | African-American race | 1.558 | 1.272-1.908 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Triglycerides (moderate risk) | 1.49 | 1.164-1.907 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Blood glucose | 2.107 | 1.171-3.791 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Age >55 years old | 0.461 | 0.367-0.579 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | African-American race | 2.173 | 1.708-2.765 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Gender (male) | 1.953 | 1.543-2.472 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | BP medications nonadherence | 2.242 | 1.580-3.183 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | History of atrial fibrillation | 0.477 | 0.242-0.938 | |
| Dave et al. (2013) [16] | Case control | 2004-2007 | 2663 | 1158 | Smoker | 1.376 | 1.029-1.842 | |
| Bhatt et al. (2016) [17] | Cohort | January 2003-October 2007 | 30018 | 5587 | Atrial fibrillation | 1.87 | 1.59-2.21 | Uncontrolled SBP |
| Ofedal et al. (2018) | Cohort | September 2010-August 2015 | 385 | 104 | Number of antihypertensive drug | 1.83 | 1.46-2.30 | Uncontrolled BP |
| Ofedal et al. (2018) | Cohort | September 2010-August 2015 | 385 | 104 | HDL cholesterol | 0.51 | 0.31-0.84 | |
| Ofedal et al. (2018) | Cohort | September 2010-August 2015 | 385 | 104 | Triglycerides | 1.45 | 1.14-1.86 | |
| Ofedal et al. (2018) | Cohort | September 2010-August 2015 | 385 | 104 | Fasting blood glucose | 1.26 | 1.07-1.49 | |
| Ofedal et al. (2018) | Cohort | September 2010-August 2015 | 385 | 104 | HbA1c | 1.47 | 1.08-2.01 | |

NE: not explained; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Searching was limited only for the English language articles. The article type was limited only to the original journal articles. The publication period was limited only from 2010 to December 2019. Articles with potentially relevant titles were then reviewed based on their abstracts, while the irrelevant ones were excluded. The articles with potentially relevant abstracts were then fully reviewed. Meanwhile, the irrelevant ones were excluded. Furthermore, an article will be excluded if the research design is not a case control or cohort study and the variable is not the uncontrolled hypertension in stroke.

2.4. Data Analysis. The data were analyzed to obtain the value of pooled odds ratio (POR), that is, the combined odds ratio values from the related studies. The data were analyzed using the Mantel-Haenszel method with both fixed and random-effect model proposed by DerSimonian-Laird. The data were then analyzed using the Review Manager 5.3 (Rev Man 5.3).

3. Results

The searching made using specific keywords was to identify 1868 articles and then review the article titles, abstracts, and full-texts. Irrelevant articles were then excluded. The included seven studies were reviewed since correlated with the risk factors of the uncontrolled hypertension in stroke (Table 1). The research variables were systematically reviewed, while the meta-analysis was the modifiable risk factors including BP medication nonadherence, stage of hypertension, and the use of antihypertensive drugs.

The effect of medication nonadherence on the uncontrolled hypertension was presented in Figure 2. Figure 2 shows that the medication nonadherence contributed to the uncontrolled hypertension \( \text{POR} = 2.23 (95\% CI 1.71 - 2.89) \). There was heterogeneity among studies regarding to the role of medication nonadherence factor on the uncontrolled hypertension \( p = 0.342; I^2 = 6.7 \% \). It indicates that the variation among studies was homogeneous. The funnel plots to identify the publication bias among studies related to the medication nonadherence factor on the uncontrolled hypertension were presented in Figure 3. Figure 3 shows that there was no significant publication bias for the studies related to the medication nonadherence factor on the uncontrolled hypertension, respectively, based on the Egger’s test \( p = 0.997 \) and Begg’s test \( p = 0.602 \).

Figure 4 shows that the use of hypertensive drugs contributed to the uncontrolled hypertension \( \text{POR} = 1.14 (95\% CI 1.02 - 1.27) \). There was heterogeneity among studies regarding the role of the use of antihypertensive drugs on the uncontrolled hypertension \( p = 0.001; I^2 = 90.9\% \). It shows that the variation among studies was heterogeneous. The funnel plots to identify the publication bias among studies related to the use of antihypertensive drugs on the uncontrolled hypertension, respectively, based on the Egger’s test \( p = 0.602 \) and Begg’s test \( p = 0.394 \).

Figure 6 shows that the stage of hypertension contributed to the uncontrolled hypertension \( \text{POR} = 1.14 (95\% CI 1.02 - 1.27) \). There was heterogeneity among studies regarding the role of stage of hypertension on the uncontrolled hypertension \( p = 0.000; I^2 = 97.1 \% \). This indicates that the variation between studies was heterogeneous. The funnel plots to identify publication bias between studies related to the stage hypertension and uncontrolled hypertension were presented in Figure 7. Figure 7 shows that there was no significant publication bias on the studies related to the stage of hypertension on the uncontrolled hypertension, respectively, based on the Egger’s test \( p = 0.222 \) and Begg’s test \( p = 0.602 \).

Meta-analysis results showed the effect of diabetes on the uncontrolled hypertension (Figure 8). Figure 8 shows that stage of diabetes did not contribute to the uncontrolled hypertension \( \text{POR} = 0.71 (95\% CI 0.52 - 0.99) \). There was heterogeneity among studies regarding the role of diabetes on the uncontrolled hypertension \( p = 0.001; I^2 = 96.5 \% \). This indicates that the variation between studies was heterogeneous. The funnel plots to identify the publication bias among studies related to diabetes on the uncontrolled hypertension were presented Figure 9. Figure 9 shows that there was no significant publication bias among studies related to diabetes on the uncontrolled hypertension.
| Study ID                  | OR (95% CI) | % Weight |
|--------------------------|-------------|----------|
| Sarfo et al (2016)       | 1.30 (1.06, 1.60) | 49.75    |
| Offedal et al (2018)     | 1.83 (1.46, 2.30) | 40.83    |
| Nidhinandana (2014)      | 0.53 (0.33, 0.85) | 9.42     |
| Overall (I-squared = 90.9%, $p = 0.000$) | 1.37 (1.19, 1.59) | 100.00   |

Figure 3: Funnel plot role of medication nonadherence on the uncontrolled hypertension.

Figure 4: Effect size of use of antihypertensive drugs on the uncontrolled hypertension.

Figure 5: Funnel plots role of use of antihypertensive drugs on the uncontrolled hypertension.
| Study ID | OR (95% CI) | % Weight |
|----------|-------------|----------|
| Sarfo et al (2016) | 1.31 (1.17, 1.47) | 91.35 |
| Nidhinandana et al (a) (2014) | 0.30 (0.15, 0.59) | 2.54 |
| Nidhinandana et al (b) (2014) | 0.24 (0.12, 0.29) | 6.11 |
| Overall (I-squared = 97.1%, p = 0.000) | 1.14 (1.02, 1.27) | 100.00 |

**Figure 6: Effect size of hypertension stage on the uncontrolled hypertension.**

---

| Study ID | OR (95% CI) | % Weight |
|----------|-------------|----------|
| Nidhinandana et al (2014) | 2.11 (1.17, 3.79) | 30.65 |
| Dave et al (2013) | 2.11 (1.17, 3.79) | 30.65 |
| Overall (I-squared = 96.5%, p = 0.000) | 0.71 (0.52, 0.99) | 100.00 |

**Figure 8: Effect size of diabetes on the uncontrolled hypertension.**
Figure 9: Funnel plots role of diabetes on the uncontrolled hypertension.

| Study ID          | OR (95% CI)       | % Weight |
|-------------------|-------------------|----------|
| Bhatt et al (2016)| 0.48 (0.24, 0.94) | 5.50     |
| Dave et al (2014) | 1.87 (1.59, 2.21) | 94.50    |
| Overall (I-squared = 93.1%, p = 0.000) | 1.74 (1.48, 2.04) | 100.00   |

Figure 10: Effect size of atrial fibrillation on the uncontrolled hypertension.

Figure 11: Funnel plots role of atrial fibrillation on the uncontrolled hypertension.
diabetes on the uncontrolled hypertension, respectively, based on the Egger’s test (p = 0.221) and Begg’s test (p = 0.602).

The meta-analysis results showed the effect of atrial fibrillation on the uncontrolled hypertension (Figure 10). Figure 10 indicates that the atrial fibrillation contributed to the uncontrolled hypertension pooled odds ratio (POR) = 1.74 (95%CI 1.48 − 2.04). There was heterogeneity among studies regarding the role of atrial fibrillation factor on the uncontrolled hypertension (p heterogeneity = 0.000; I² = 93.1%) This shows that the variation among studies was heterogeneous. The funnel plots to identify publication bias among studies related to the atrial fibrillation on the uncontrolled hypertension were presented in Figure 11. Figure 11 shows that there was no significant publication bias among the studies related to the atrial fibrillation on the uncontrolled hypertension, respectively, based on the Egger’s test (p = 0.856) and Begg’s test (p = 0.317).

Figure 12 shows that triglyceride contributed to the uncontrolled hypertension pooled odds ratio (POR) = 1.47 (95%CI 1.23 − 1.75). There was heterogeneity among studies regarding the role of triglyceride factor on the uncontrolled hypertension (p heterogeneity = 0.879; I² = 0%). This indicates that the variation among studies was homogeneous. The funnel plots to identify the publication bias among studies related to the triglyceride factor on the uncontrolled hypertension were presented in Figure 13. Figure 13 shows that there was no significant publication bias among the studies related to the triglyceride factor on the uncontrolled hypertension, respectively, based on the Egger’s test (p = 0.547) and Begg’s test (p = 0.317).

The meta-analysis results showed that age was the nonmodifiable risk factor of the uncontrolled hypertension (Figure 14). Figure 14 indicates that age did not contribute to the uncontrolled hypertension pooled odds ratio (POR) = 1.03 (95%CI 0.89 − 1.18). There was heterogeneity among studies regarding the role of age on the uncontrolled hypertension p( heterogeneity = <0.001; I² = 97.5%). This indicates that the variation among studies was heterogeneous. The
funnel plots were to identify the publication bias among studies related to the age on the uncontrolled hypertension (Figure 15). Figure 15 shows that there was no significant publication bias among studies related to the age on the uncontrolled hypertension, respectively, based on the Egger’s test ($p = 0.919$) and Begg’s test ($p = 0.520$).

4. Discussion

The meta-analysis results showed that the modifiable risk factors of the uncontrolled hypertension in stroke was treatment nonadherence with the highest POR value ($\text{POR} = 2.23$ [95%CI 1.71 - 2.89], $p = 0.0342$; $I^2 = 6.7\%$) followed by atrial fibrillation ($\text{POR} = 1.74$ [95%CI 1.48 - 2.04]), triglycerides ($\text{POR} = 1.47$ [95%CI 1.23 - 1.75], $p = 0.879$; $I^2 = 0\%$, $p = <0.001$; $I^2 = 93.1\%$), stage of hypertension ($\text{POR} = 1.14$ [95%CI 1.02 - 1.27], $p = <0.001$; $I^2 = 97.1\%$), and use of antihypertensive drugs ($\text{POR} = 1.13$ [95%CI 1.19 - 1.59], $p = 0.001$; $I^2 = 90.9\%$). Medication nonadherence and triglycerides had the homogeneous variations among the studies, while the others had heterogeneous ones.

Based on the research results, 80.73% of stroke patients had the uncontrolled blood pressure, and 75.11% had the antihypertensive medication nonadherent. The main reasons to the treatment nonadherence were forgetfulness (58.08%), lack of confidence in obtaining the long-term antihypertensive treatment (27.75%), and not realizing the importance of long-term treatment (24.75%) [14]. A high prevalence of uncontrolled hypertension and medication nonadherence was also shown in the other studies with 67.1% of patients had the uncontrolled blood pressure and 56.1% had the therapy nonadherence [15]. However, other studies showed that the prevalence of uncontrolled hypertension in stroke patients was lower with 43.5% had the uncontrolled systolic blood pressure (SBP), 22.8% had the uncontrolled diastolic blood pressure (DBP), and 18.5% had the combination of SBP and DBP. One risk factor in this study was related to the medication nonadherence which became the obstacles to adherence.
including forgetfulness, believing in the unwanted side effects, health irresponsibility, absence of symptoms, and problems with access to treatments and drugs [16].

The second factor influencing the uncontrolled hypertension in this study was atrial fibrillation. The prevalence of atrial fibrillation in stroke patients in some studies was 4.3% [16]. Meanwhile, the other studies included in this study had the prevalence of atrial fibrillation in stroke patients by 8.6% [17]. Atrial fibrillation is one of the most common cardiac arrhythmias found to increase the risks of heart failure and stroke as well as to increase the mortality in cardiovascular diseases [18, 19]. In some studies on patients with hypertension, the prevalence of atrial fibrillation was higher in the uncontrolled hypertension patients than that in the controlled hypertension [20]. The risk of atrial fibrillation was decreased with the use of antihypertensive drugs, such as beta blockers and angiotensin converting enzyme inhibitors (ACEI) [21–23].

Triglycerides affect the uncontrolled hypertension. High triglyceride levels can lead to the thickening walls of blood vessels which can increase the risk of stroke and heart disease since related to the occurring arterial plaque as a covariate of the uncontrolled hypertension in stroke patients [24].

Stage of hypertension was the other factor having a significant effect in this study. Every 10 mmHg increase in systolic blood pressure (SBP) will also increase the risk of uncontrolled hypertension in the poststroke patients [25]. Other studies explained that stage of hypertension was associated with the controlled blood pressure (stage I at the discharge of OR = 0.30 [95% CI = 0.15 – 0.59] and stage II at the discharge of OR = 0.24 [95% CI = 0.12 – 0.49]) [26].

The use of antihypertensive drugs also influenced the uncontrolled hypertension. The optimal blood pressure target for the secondary prevention in ischemic stroke patients was still debatable [27]. The results of study conducted by Oftedal et al. [24] revealed that the patients with uncontrolled hypertension used a higher number of antihypertensive drugs than those with the controlled hypertension, although the average number of drugs was < 2 in both groups, less than 10% used 3 or more antihypertensive drugs. Thus, the systematic antihypertensive treatments given to the ischemic stroke patients with hypertension were more potential to reduce the high risk of the occurring vascular disorders [28].

5. Conclusion

Medication nonadherence, stage of hypertension, atrial fibrillation, triglycerides, and use of antihypertensive drugs had a significant effect on the uncontrolled hypertension in stroke. The medication nonadherence and triglycerides strongly affected the uncontrolled hypertension in stroke. To improve the controlled blood pressure in stroke patients, some efforts are greatly required to overcome the obstacles to adherence.

Data Availability

All data is attached in the table, and the data analysis has been shown in the figure.

Conflicts of Interest

The authors declare that there is no funding and conflict of interest.

Acknowledgments

The authors would like to thank Dr. Ricvan Dana Nindrea who has given valuable contributions in analyzing the data using the Rev. Man. 5.

References

[1] N. Venketasubramanian, B. W. Yoon, J. Pandian, and J. C. Navarro, "Stroke epidemiology in south, east, and South-East Asia: a review," Journal of Stroke, vol. 19, no. 3, pp. 286–294, 2017.
[2] V. L. Feigin, R. V. Krishnamurthi, P. Parmar et al., “Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study,” Neuroepidemiology, vol. 45, no. 3, pp. 161–176, 2015.
[3] R. I. Kemenkes, Laporan Riset Kesehatan Dasar Tahun 2018, Badan Penelitian Dan Pengembangan Kesehatan Kemenkes RI, Jakarta, 2019.
[4] J. Slark and P. Sharma, “Risk awareness in secondary stroke prevention: a review of the literature,” Journal of the Royal Society of Medicine Cardiovascular Disease, vol. 3, article 20480041351473, 2013.
[5] A. K. Boehme, C. Esenwa, and M. S. V. Elkind, “Stroke risk factors, genetics and prevention,” Circulation Research, vol. 120, no. 3, pp. 472–495, 2017.
[6] L. Ghani, L. K. Mihardja, and Delima, “Dominant risk factors of stroke in Indonesia,” Bulletin Penelitian Kesehatan, vol. 44, no. 1, pp. 49–58, 2016.
[7] L. B. Goldstein, R. Adams, M. J. Albert et al., “Primary prevention of ischemic stroke,” 2006, Mei 2017, http://stroke.ahajournals.org/.
[8] S. L. Lee, “Awareness of blood pressure among older adults: a cross sectional descriptive study,” International Journal of Nursing Studies, vol. 44, pp. 796–804, 2007.
[9] A. Malik, Y. Yoshida, T. Erkin, D. Salim, and M. Hamajima, “Hypertension-related knowledge, practice and drug adherence among inpatients of a hospital in Samarkand, Uzbekistan,” Nagoya Journal of Medical Science, vol. 76, no. 3–4, pp. 255–263, 2014.
[10] M. A. Ghembaza, Y. Senoussaoui, M. K. Tani, and K. Meguenni, “Impact of patient knowledge of hypertension complications on adherence to antihypertensive therapy,” Current Hypertensive Reviews, vol. 10, no. 1, pp. 41–48, 2014.
[11] H. Y. Song and K. A. Nam, “Effectiveness of stroke risk self-management intervention for adult with prehypertension,” Asian Nursing Research, vol. 9, no. 4, pp. 328–335, 2015.
[12] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, article e1000097, 2009.
[13] B. Tesfaye, D. Haile, B. Lake, T. Belachew, T. Tesfaye, and H. Abera, “Uncontrolled hypertension and associated factors among adult hypertensive patients on follow-up at Jimma University Teaching and Specialized Hospital: cross-sectional
study,” Research Report in Clinical Cardiology, vol. 8, pp. 21–29, 2017.

[14] M. J. Chen, C. C. Wu, L. H. Wan, G. Y. Zou, and S. H. Neidlinger, “Association Between medication adherence and admission blood pressure among patients with ischemic stroke,” Journal of Cardiovascular Nursing, vol. 34, no. 2, pp. E1–E8, 2019.

[15] J. M. P. Vilaubi, D. O. Beltran, A. Q. Goncalves et al., “Adherence to European clinical practice guidelines for secondary prevention of cardiovascular disease: a cohort study,” International Journal of Environmental Research and Public Health, vol. 15, no. 6, article 1233, 2018.

[16] G. J. Dave, D. L. Bilbeau, M. R. Schulz et al., “Predictors of uncontrolled hypertension in the stroke belt,” The Journal of Clinical Hypertension, vol. 15, no. 8, pp. 562–569, 2013.

[17] H. Bhatt, G. M. Gamboa, M. M. Safford, E. Z. Soliman, and S. P. Glasser, “Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study,” Journal of American Society Hypertension, vol. 10, no. 7, pp. 578–586.e5, 2016.

[18] A. J. Camm, P. Kirchhof, and G. Y. Lip, “Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 31, no. 19, pp. 2369–2429, 2010.

[19] P. Verdecchia, G. Mazzotta, and F. Angeli, “Above which blood pressure level does the risk of atrial fibrillation increase?,” Hypertension, vol. 59, no. 2, pp. 184–185, 2012.

[20] M. C. Thomas, S. Dublin, R. C. Kaplan et al., “Blood pressure control and risk of incident atrial fibrillation,” American Journal Hypertension, vol. 21, no. 10, pp. 2369–2429, 2010.

[21] A. J. Manolis, E. A. Rosei, A. Coca et al., “Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment,” Journal of Hypertension, vol. 30, no. 2, pp. 239–252, 2012.

[22] S. C. Marrot, S. F. Nielsen, M. Benn, and B. G. Nordestgaard, “Antihypertensive treatment and risk of atrial fibrillation: a nationwide study,” European Heart Journal, vol. 35, no. 18, pp. 1205–1214, 2014.

[23] I. A. Nasr, A. Bouzamondo, and J. S. Hulot, “Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis,” European Heart Journal, vol. 28, no. 4, pp. 457–462, 2007.

[24] Å. Oftedal, E. Gerds, U. Waje-Andreassen et al., “Prevalence and covariates of uncontrolled hypertension in ischemic stroke survivors: the Norwegian stroke in the young study,” Blood Pressure, vol. 27, no. 3, pp. 173–180, 2018.

[25] F. S. Sarfo, G. Kyem, B. Ovbiagele et al., “One-year rates determinants of poststroke systolic blood pressure control among Ghanaians,” Journal of Stroke and Cerebrovascular Diseases, vol. 26, no. 1, pp. 78–86, 2017.

[26] S. Nidhinandana, D. Ratanakorn, and N. Charnnarong, “Blood pressure control among stroke patients in Thailand—the i-STROKE study,” Journal Stroke Cerebrovascular Diseases, vol. 23, no. 3, pp. 476–483, 2014.